

# Index

## A

Afatinib, 9  
AG-120, 72  
AGI-5198, 71  
AGI-6780, 71  
Allograft, 30  
AMPK, 124  
Anaplasia, 172  
Angiogenesis, 9  
Annual incidence, 2  
Anti-angiogenic therapy, 9  
Anticancer agents, 97  
Anti-ELTD1 treatment, 9  
Antigenic, 100  
Antisense therapies, 109  
Apoptosis, 145  
Area under the curve, 154  
Artificial intelligence, 157  
Astrocytes, 2  
Astrocytomas, 172  
ATP, 124  
AZD9291, 9

## B

Bevacizumab, 8, 81  
BIRC5, 142  
Bisdemethoxycurcumin, 141  
Blood brain barrier, 4  
Brain mapping, 187  
Brain tumor-related epilepsy, 199

## C

Cancer metabolism, 98  
Cancer stem cells, 47  
CCNU, 152  
Cellular metabolism, 67, 68  
CGGA, 153  
Chemoradiation, 80  
Chemotherapies, 64  
Cholesterol derivatives, 97, 106, 107, 108  
Cholesterol metabolism, 102  
Classic glioblastoma, 174  
Classification, 100  
Clinical practice, 174  
Clinical presentation, 121, 203  
Clinical trials, 177, 182  
Comparative dosimetry, 88  
Computational approaches, 153, 159  
Concordance index, 154  
Convolutional neural network, 157, 189  
Cox's proportional hazards model, 154  
Cre-LoxP, 20, 21, 23  
CRISPR/Cas9, 26  
Curcumin, 139  
Current challenges, 175

## D

D-2HG, 63, 66  
Deep learning, 157  
Desmoplastic infantile astrocytoma, 212  
Diffuse gliomas, 172

Digital pathology, 162  
DIPG, 54, 85  
Direct electrical stimulation, 188  
DS-1001b, 72

## E

EGFR, 9, 174  
EGFR/HER1, 8  
ELTD1, 1  
Energy metabolism, 121, 123  
Ependymoma, 54  
Epidemiology, 99, 200  
Epigenetic alternations, 66  
Epigenomic repression, 69

## F

Functional modules, 176  
Future directions, 171, 176

## G

Gangliocytoma, 212  
Ganglioglioma, 212  
Gap junctions, 202  
Gefitinib, 9  
Genetic changes, 51  
Genetic characteristics, 100  
Genetic characterization, 162  
GL261, 1,8  
Glioblastoma, 1, 5, 97, 102, 121, 152, 173  
Glioblastoma-associated edema, 128  
Glioma cell lines, 145  
Glioma patients, 79  
Gliomagenesis, 124  
Gliomas, 54, 139, 151, 171  
Glioneuronal tumors, 211  
Grade I-IV, 172

Gross resection, 80  
Growth, 61  
GTP synthesis pathways, 127

## H

High-grade glioma, 152  
Histone methylation, 66  
Humanized mouse models, 34

## I

IDH, 61, 63, 64, 70  
IGF-IR, 109  
Imaging, 160, 213  
Immune checkpoint therapy, 30  
Immunocompromised mice, 33  
IMP dehydrogenase, 127  
IMPDH2, 128  
In utero electroporation, 85  
Inflammation, 128  
Ionizing radiation, 80  
Isocitrate dehydrogenase 1, 61, 100

## J

Junction complexes, 5

## K

Karnofsky performance  
status, 152

## L

Late effects, 219, 221  
Left hemisphere, 191  
Lipo-neurocytoma, 212  
Liver X Receptors, 104  
Lower grade gliomas, 152

**M**

m<sup>6</sup>A, 66  
Machine learning, 154  
Magnetic resonance imaging, 157  
Malignancy, 126  
Management, 199, 203  
Medulloblastoma, 52  
Mesenchymal glioblastoma, 174  
Metabolic characterization, 63  
Metabolic reprogramming, 126  
Metabolic therapy, 97  
Metabolism, 61, 101  
MGMT, 70, 100, 152  
Mitochondria, 108  
MMF, 127  
Model validation, 154  
Molecular analysis, 79  
Molecular characterization, 162, 217  
Molecular genetics, 202  
Molecular markers, 171  
Molecular profile, 174  
Mouse models, 15, 79, 84  
Mycophenolate mofetil, 127  
Mycophenolic acid, 127

**N**

N<sup>6</sup>-methyladenosine, 66  
Nanotherapy, 109  
Neoangiogenesis, 129  
Neural glioblastoma, 174  
Neural stem cells, 2  
Neuropsychological testing, 187  
Neurotransmitters, 202  
NF1, 174  
NOD/SCID, 6  
Non-coding RNA, 83  
Non-diffuse gliomas, 172

Notch/DLL4, 9  
Novel approaches, 151  
NRF2, 143

**O**

O<sup>6</sup>-methylguanine-DNA methyltransferase, 100, 152  
Obesity-associated protein, 66  
OKN-007, 10  
Oligodendrocytes, 2  
Osimertinib, 9  
Outcomes, 79  
Oxidative stress, 145  
Oxysterols, 106

**P**

Papillary glioneuronal tumor, 212  
Paradoxical outcomes, 69  
Paraganglioma, 212  
Pathogenesis, 100, 199, 200  
Pathology, 216  
Patient derived orthotopic xenograft, 7  
PDGFRA, 174  
Pediatric brain tumors, 47  
Pediatric, 55  
Peritumoral environmental changes, 202  
Personalized medicine, 83  
Pre-clinical models, 1, 5  
Primary glioblastoma, 2  
Procarbazine, 152  
Prognosis, 171  
Prognostic classes, 152  
Proneural glioblastoma, 174  
Prospective trials, 155  
Proton beam therapy, 87  
Proton therapy, 79  
PTEN, 2, 100, 174

**Q**

qPCR, 82, 144  
Qualitative analysis, 5  
Quality of life, 89, 192, 193, 200  
Quercetin, 106  
Quiescence, 53

**R**

Radiation therapy, 125, 126, 220  
Radiation, 64  
Radiomics, 159  
Random forest, 157, 158  
RANK, 143  
Real-time, 187  
Receiver operating characteristics curve, 154  
Recurrent surgery, 195  
Recursive partitioning analysis, 154  
Redox status, 65  
Response to treatment, 161  
Right hemisphere, 191  
Risk factors, 100  
RNA-based therapies, 84  
RNA-binding proteins, 104

**S**

SCID mice, 6  
Secondary glioblastoma, 2  
Seizures, 201  
Single-cell RNA-sequencing, 82  
Sonic hedgehog, 51  
SREBP, 105  
Standardization of methods, 180  
Statins, 105  
Stereotactic radiosurgery, 87  
Stress resilience, 69

Stresses, 124  
Stroke-associated edema, 128  
Stupp protocol, 80  
Support vector machine, 157, 158  
Surgical management, 206, 219  
Surgical treatment, 204  
Survival prediction, 151  
Symptom control, 219  
Systemic therapy, 145

**T**

T2FLAIR, 161  
Targeting energy metabolism, 121  
TCGA, 152  
Technical challenge, 68  
Temozolomide, 81, 152  
TERT, 174  
The Cancer Genome Atlas, 152  
The Cancer Imaging Archive, 161  
Therapeutic efficacy, 64  
Therapeutic resistance, 121  
Therapeutic sensitivity, 70  
Therapeutics, 8, 61  
Therapy-limiting factors, 3  
Toxicity, 142  
TP53, 100, 174  
Transforming growth factor  $\beta$ 1, 10  
Transposons, 24, 25  
Treating pediatric brain tumors, 56  
Treatment options, 82  
Treatment resistance, 50  
Tumor growth rate, 201  
Tumor invasiveness, 144  
Tumor location, 201  
Tumor microenvironment, 30  
Tumor resection, 187  
Tumor treating fields, 64

Tumor treating fields, 81  
Tumor-associated edema, 121  
Tumorigenesis, 9  
Turmeric, 141

## U

Ubiquitin ligase, 104  
Ubiquitination, 144

## V

Validation, 191  
Vascular endothelial growth factor, 2  
Vincristine, 152  
Viral vector delivery system, 28

## W

WHO 2016 classification, 172  
Whole brain radiation therapy, 30  
Wnt, 143

## X

Xenograft mouse models, 5

## Y

Young patients, 195

## Z

Zebra fish, 129

Doi: <https://doi.org/10.36255/exonpublications.gliomas.2021.index>

